Financial News Feed

Shares of Akari Therapeutics PLC rocketed 61% to pace all premarket gainers in very active trading Wednesday, after the biopharmaceutical company said its…

Read more

The thinly traded, nano-cap biotech Akari Therapeutics PLC (NASDAQ: AKTX) gap-opened higher Wednesday morning, and shares were advancing strongly on …

Read more

Anyone researching Akari Therapeutics, Plc (NASDAQ:AKTX) might want to consider the historical volatility of the share…

Read more

Akari (AKTX) presents favorable safety data from part A of an early-stage study on nomacopan for treating moderate to severe atopic keratoconjunctivitis. Shares appreciate.

Read more

Shares of Akari Therapeutics PLC (NASDAQ: AKTX ) — a thinly traded nano-cap biotech focusing on therapies for autoimmune and inflammatory diseases — were soaring Wednesday. What Happened Akari announced positive results for Part A of a Phase 1/2 study dubbed TRACKER that evaluated the safety and efficacy of its topical nomacopan in moderate to severe atopic keratoconjunctivitis. The Part A portion of the midstage study evaluated three patients who were administered nomacopan eye drops twice daily in addition to cyclosporin, the standard of care, for up to 56 days. The … Full story available on Benzinga.com

Read more

Akari Therapeutics EPS beats by $0.05
12:06pm, Wednesday, 29'th May 2019

Read more

In an experimental back of the eye, autoimmune uveitis (EAU) model to be reported in a poster presentation at ARVO 2019, nomacopan (Coversin) and its long acting variants administered intravitreally, reported: ○ Significant improvement in clinical scoring versus control ○ Co-localization of LTB4 and C5a receptors in retinal inflammatory cells seen for the first time ○ Significant downregulation of pro-inflammatory T-helper 17 cells and the inflammatory cytokine IL-17 ○ Efficacy of LTB4 and C5 inhibition, supporting its potential as a novel, non-steroidal therapy across a range of severe ‘back-of-eye' diseases In a "first in eye" Phase I/II study in atopic keratoconjunctivitis (AKC) initial surface of the eye data from the first two patients, treated topically, nomacopan (Coversin) demonstrated: ○ No serious drug related adverse events and good tolerability ○ Rapid improvement in mean comfort and composite efficacy endpoint scores compared to baseline on cyclosporin ○ In allergic conjunctivitis, an eye surface disease, elevated levels of LTB4 were observed NEW YORK and LONDON, April 26, 2019 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ: AKTX ), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, announced encouraging new data in both the surface and the back of the eye. "This positive initial data from our ophthalmology program supports the potential efficacy of LTB4 and C5 inhibition in eye surface and back-of-the-eye diseases.

Read more

NEW YORK , April 24, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACB, AKTX, ATOS, BA, and RBZ. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. ACB: Full story available on Benzinga.com

Read more

Akari Therapeutics reports Q4 results
08:13pm, Tuesday, 23'rd Apr 2019
Akari Therapeutics (AKTX): Q4 GAAP EPS of $0.00. Cash of $5.4M Press Release

Read more

Gainers: Atossa Genetics (ATOS) +28%. Immunic (IMUX) +22%. Akari Therapeutics (AKTX) +19%. Superconductor Technologies (SCON) +18%. X4 Pharmaceuticals (XFO

Read more

Akari Therapeutics PLC (NASDAQ: AKTX ) shares were surging Tuesday, breaking above the $4 barrier for the first time in about a month. What Happened The microcap biotech — which focuses on therapies for autoimmune and inflammatory diseases — announced positive Phase 2 results for nomacopan, or Coversin, which is being evaluated for bullous pemphigoid, a severe inflammatory skin disease. Akari is also evaluating Coversin for pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy. The midstage trial studied up to nine mild-to-moderate bullous pemphigoid patients in a six-week, open-label, single-arm study that evaluated safety and efficacy. They results measured using the bullous pemphigoid … Full story available on Benzinga.com

Read more

This is a contrast between Rubius Therapeutics Inc. (NASDAQ:RUBY) and Akari Therapeutics Plc (NASDAQ:AKTX) based on their dividends, analyst recommendations, institutional ownership, profitability, ri

Read more

Proudly made at

ROCKIT